MAGNAMED | Novel magnetic nanostructures for medical applications

Summary
MAGNAMED designs, fabricates, and assesses novel magnetic nanostructures (MNS) with unique spin configurations for innovative diagnostics and therapy techniques. An early stage detection and an effective treatment are keystones to reduce cancer mortality. Current clinical procedures fail to detect small concentration of tumoral biomarkers. Magnetic nanoparticles (MNP), like beads, have attracted much attention for their capability to improve cancer detection limits and treatment technologies. However, there are several limitations to the use of MNP. As an emerging alternative, MNS are being explored. Unlike MNP, MNS (e.g. nanodisks) present a planar shape with novel properties for diagnosis: high magnetic moment and large size, which can significantly improve the sensor sensitivity, and for therapy: due to their planar shape, alternate magnetic fields provoke a magneto-mechanical action on the cell membrane that triggers cell death. The efficiency of MNS in these two medical applications has not been investigated yet for MNS at the nanometer scale. The challenge of this project is to produce MNS with nanometer dimensions suitable for medical applications. Several lithography techniques will be used to fabricate MNS in vortex and antiferromagnetic spin configurations covering a broad size range (40 to 4000 nm). After functionalization, MNS will be exploited in: (i) Diagnostics, using giant magnetoresistance (GMR) sensors for the detection of tumoral biomarkers (dermcidin and carcinoembryonic antigen), and (ii) Therapy, effectiveness of tumoral cell annihilation by the magneto-mechanical action of MNS will be evaluated in vitro assays of melanoma and colorectal cancer cells. MAGNAMED is a cross-sectoral and interdisciplinary project involving Physics, Chemistry and Medicine. Findings will have a medium-term impact on the European strategy for early stage detection of cancer and a long-term impact on the development of novel and groundbreaking therapeutics techniques.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/734801
Start date: 01-04-2017
End date: 31-05-2023
Total budget - Public funding: 846 000,00 Euro - 846 000,00 Euro
Cordis data

Original description

MAGNAMED designs, fabricates, and assesses novel magnetic nanostructures (MNS) with unique spin configurations for innovative diagnostics and therapy techniques. An early stage detection and an effective treatment are keystones to reduce cancer mortality. Current clinical procedures fail to detect small concentration of tumoral biomarkers. Magnetic nanoparticles (MNP), like beads, have attracted much attention for their capability to improve cancer detection limits and treatment technologies. However, there are several limitations to the use of MNP. As an emerging alternative, MNS are being explored. Unlike MNP, MNS (e.g. nanodisks) present a planar shape with novel properties for diagnosis: high magnetic moment and large size, which can significantly improve the sensor sensitivity, and for therapy: due to their planar shape, alternate magnetic fields provoke a magneto-mechanical action on the cell membrane that triggers cell death. The efficiency of MNS in these two medical applications has not been investigated yet for MNS at the nanometer scale. The challenge of this project is to produce MNS with nanometer dimensions suitable for medical applications. Several lithography techniques will be used to fabricate MNS in vortex and antiferromagnetic spin configurations covering a broad size range (40 to 4000 nm). After functionalization, MNS will be exploited in: (i) Diagnostics, using giant magnetoresistance (GMR) sensors for the detection of tumoral biomarkers (dermcidin and carcinoembryonic antigen), and (ii) Therapy, effectiveness of tumoral cell annihilation by the magneto-mechanical action of MNS will be evaluated in vitro assays of melanoma and colorectal cancer cells. MAGNAMED is a cross-sectoral and interdisciplinary project involving Physics, Chemistry and Medicine. Findings will have a medium-term impact on the European strategy for early stage detection of cancer and a long-term impact on the development of novel and groundbreaking therapeutics techniques.

Status

CLOSED

Call topic

MSCA-RISE-2016

Update Date

28-04-2024
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon 2020
H2020-EU.1. EXCELLENT SCIENCE
H2020-EU.1.3. EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions (MSCA)
H2020-EU.1.3.3. Stimulating innovation by means of cross-fertilisation of knowledge
H2020-MSCA-RISE-2016
MSCA-RISE-2016